October 22, 2016 10:17 PM ET


Company Overview of Agios Pharmaceuticals, Inc.

Key Executives for Agios Pharmaceuticals, Inc.

NameBoard RelationshipsTitleAge
David P. Schenkein M.D.54 RelationshipsChief Executive Officer, President and Director59
Lewis Clayton Cantley Ph.D.69 RelationshipsCo-Founder, Director, Member of Scientific Advisory Board and Chairman of Science & Technology Committee67
Tak Wah Mak Ph.D., D.Sc.,FRSC155 RelationshipsCo-Founder and Member of Scientific Advisory Board70
Craig B. Thompson M.D.131 RelationshipsCo-Founder and Chairman of Scientific Advisory Board63
Andrew Hirsch 12 RelationshipsChief Financial Officer45
View More Key Executives

Agios Pharmaceuticals, Inc. Board Members*

NameBoard RelationshipsPrimary CompanyAge
John M. Maraganore M.D., Ph.D. 169 RelationshipsAlnylam Pharmaceuticals, Inc.53
David P. Schenkein M.D. 54 RelationshipsAgios Pharmaceuticals, Inc.59
Lewis Clayton Cantley Ph.D. 69 RelationshipsAgios Pharmaceuticals, Inc.67
Tak Wah Mak Ph.D., D.Sc.,FRSC 155 RelationshipsAgios Pharmaceuticals, Inc.70
Craig B. Thompson M.D. 131 RelationshipsAgios Pharmaceuticals, Inc.63
View All Board Members

Agios Pharmaceuticals, Inc. Executive Committees*

Committee NameChairpersonBoard RelationshipsMembers
Audit Committee M.B.A.Paul J. Clancy21 Relationships3 Executives
Compensation Committee Kaye I. Foster-Cheek39 Relationships3 Executives
Nominating Committee Kaye I. Foster-Cheek39 Relationships3 Executives
Corporate Governance Committee Kaye I. Foster-Cheek39 Relationships3 Executives
Advisory Board M.D.Craig B. Thompson131 Relationships9 Executives
View Committee Details
*Data is at least as current as the most recent Definitive Proxy.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


  Industry Range
Not meaningful
Total Short Term Compensation$54.6M
Not meaningful
Total Value of Options$517.5K
Compensation as of Fiscal Year 2015
Agios Pharmaceuticals, Inc. CEO Compensation
Industry Average


4SC AG Announces Executive Changes
October 21, 2016 9:18 AM ET
Rosetta Genomics Ltd. Appoints Mark R. Willig as Chief Commercial Officer
October 20, 2016 12:40 PM ET
ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors
October 20, 2016 12:30 PM ET
Proteon Therapeutics Inc. Appoints Paul J. Hastings as Chairman of Board of Directors
October 20, 2016 12:00 PM ET
Vaxil Bio Ltd. Announces Executive Changes
October 20, 2016 11:12 AM ET

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Agios Pharmaceuticals, Inc., please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.